AMGEN INC is 20.5x more valuable than Krystal Biotech, Inc. by market capitalization ($191.70 B vs $9.37 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KRYS | AMGN |
|---|---|---|
| Market cap | $9.37 B | $191.70 B |
| US-listed rank | #989 | #79 |
| Revenue (latest FY) | $389.13M | $36.75B |
| Net income (latest FY) | $204.83M | $7.71B |
| Net margin | 52.6% | 21.0% |
| P/E (trailing FY) | 45.8 | 24.9 |
| SEC filings | 483 | 1,011 |
AMGEN INC is 20.5x more valuable than Krystal Biotech, Inc. by market capitalization ($191.70 B vs $9.37 B).
In their latest fiscal years, Krystal Biotech, Inc. reported $389.13M in revenue while AMGEN INC reported $36.75B.
Full pages: Krystal Biotech, Inc. and AMGEN INC, or browse the full rankings.